Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ipilimumab and Nivolumab Combination Therapy in Patients With Selected Immunotherapy Sensitive Advanced Rare Cancers

NCT04969887 is registered in ClinicalTrials.gov with Olivia Newton-John Cancer Research Institute as lead sponsor.

NCT NCT04969887
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04969887 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ipilimumab and Nivolumab Combination Therapy in Patients With Selected Immunotherapy Sensitive Advanced Rare Cancers
Lead sponsor
Olivia Newton-John Cancer Research Institute
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 3, 2021
Completion date
March 1, 2027
Enrollment
240 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

advanced biliary tract cancer, female reproductive system neoplasm, msi-h solid malignant tumor, neuroendocrine tumors